Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 5/20 | 0.36 |
| ▸ | PPARA | Q07869 | 5/20 | 0.36 |
| ▸ | MMP12 | P39900 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | PLAAT3 | P53816 | 3/20 | 0.35 |
| ▸ | PLAAT5 | Q96KN8 | 3/20 | 0.35 |
| ▸ | PLAAT2 | Q9NWW9 | 3/20 | 0.35 |
| ▸ | PLAAT4 | Q9UL19 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875071 | 0.86 | PPARA (0.37) | MCHR1IDO1L3MBTL1PPARGPPARA | |
| SCHEMBL874811 | 0.83 | PPARA (0.39) | MCHR1L3MBTL1PPARGPPARACNR1 | |
| SCHEMBL11000396 | 0.68 | MAOB (0.59) | MCHR1MAOBIDO1L3MBTL1CNR1 | |
| SCHEMBL9614100 | 0.68 | PPARA (0.50) | L3MBTL1PPARGPPARACNR1PLAAT3 | |
| SCHEMBL9613997 | 0.68 | PPARA (0.50) | L3MBTL1PPARGPPARACNR1PLAAT3 | |
| SCHEMBL9696793 | 0.65 | PPARA (0.43) | L3MBTL1PPARGPPARACNR1PLAAT3 | |
| SCHEMBL11824539 | 0.64 | PPARG (0.49) | MCHR1MAOBPPARGPPARAMMP12 | |
| SCHEMBL11825388 | 0.64 | PPARG (0.49) | MAOBPPARGPPARAMMP12MMP13 | |
| SCHEMBL17320186 | 0.64 | MAOB (0.53) | MCHR1MAOBL3MBTL1 | |
| SCHEMBL27294675 | 0.64 | IDO1 (0.47) | MAOBIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2014-05-29 | — | — | US | disclosed |
| EP-2619185-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012038942-A1 | MATRIX METALLOPROTEINASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148459-A1 | MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP12, MMP10 | MCHR1 4214/4885MAOB 1143/4885IDO1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.